TEVA's MAA for Olanzapine LAI in Schizophrenia Accepted in the EU
Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).
TEVA - Teva Pharmaceutical Industries Limited
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$39.29
DETAILS
HIGH:
$42.00
LOW:
$35.00
MEDIAN:
$40.00
CONSENSUS:
$39.29
UPSIDE:
15.32%
Stock News
The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults. TEV-‘749 aims to address treatment adherence in real-world settings and contribute to long-term disease management in people living with schizophrenia.1
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ("Fitch") has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB.
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, with a stable outlook, from BB+.
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.
Larry Robbins' Strategic Moves: Significant Reduction in Teva Pharmaceutical Industries Ltd
Insights into Glenview Capital Management's First Quarter 2026 Portfolio Adjustments Larry Robbins (Trades, Portfolio) recently submitted the 13F filing for th
Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.
Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeline.
Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right.
Teva's turnaround is real -- and may not be over.
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Teva to Present at the BofA Securities Health Care Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 12, 2026. The presentation will begin at 9:20 A.M. Pacific Time (12:20 P.M. Eastern Time).
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
Teva beats Q1 earnings and revenue estimates as Austedo, Ajovy and Uzedy fuel growth, lifting shares despite weaker generics performance.
Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustainability targets, which are focused on the issues most relevant to its business, patients and the planet. Teva surpassed all 2025 targets associated with its sustainability-linked bonds—totaling approximately $7.5 billion across its 2021 and 2023 issuances. These commitments reflect progress in areas such as climate action, health equity and access to medicines, linking financial and sustainability performance.
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Markets Move Lower as FOMC Anticipation Grows
Stocks are trading lower as tech and heavy anticipation surrounding today's Fed meeting and Powell speech
Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand
Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped by sales of its branded medicines.
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
For an accessible version of this Press Release, please visit www. tevapharm. com Q1 2026 revenues of ~$4. 0 billion increased by 2% in U. S.
Price Targets
Teva price target raised to $40 from $38 at Barclays
$40.00
(was $35.86)
Barclays
Teva price target raised to $42 from $41 at Piper Sandler
$42.00
(was $35.38)
Piper Sandler
Teva price target raised to $42 from $36 at UBS
$42.00
(was $35.38)
UBS
Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About'
$41.00
(was $32.64)
David Amsellem
·
Piper Sandler
Teva price target raised to $38 from $35 at Barclays
$38.00
(was $33.07)
Glen Santangelo
·
Barclays
Teva price target raised to $40 from $35 at Scotiabank
$40.00
(was $32.90)
Scotiabank
Teva price target raised to $36 from $32 at Truist
$36.00
(was $32.11)
Truist Financial
Teva price target raised, named a top 2026 idea at Jefferies
$40.00
(was $31.00)
Jefferies
Teva price target raised to $40 from $30 at Piper Sandler
$40.00
(was $30.35)
Piper Sandler
Teva price target raised to $35 from $31 at Goldman Sachs
$35.00
(was $30.06)
Goldman Sachs
Teva initiated with an Overweight at Barclays
$35.00
(was $28.33)
Barclays
Teva initiated with an Outperform at Scotiabank
$35.00
(was $28.41)
Scotiabank
Teva price target raised to $28 from $25 at Goldman Sachs
$28.00
(was $24.39)
Matt Dellatorre
·
Goldman Sachs
Teva price target raised to $28 from $26 at UBS
$28.00
(was $21.20)
Ashwani Verma
·
UBS
Teva price target raised to $28 from $25 at Barclays
$28.00
(was $21.20)
Balaji Prasad
·
Barclays
Teva Pharma (TEVA) PT Raised to $25 at Barclays
$25.00
(was $18.38)
Balaji Prasad
·
Barclays
BofA Securities Reiterates Buy Rating on Teva Pharma (TEVA)
$22.00
(was $17.75)
Jason Gerberry
·
Bank of America Securities
Teva Pharma (TEVA) PT Raised to $26 at UBS
$26.00
(was $18.43)
Ashwani Verma
·
UBS
Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)
$23.00
(was $18.61)
David Amsellem
·
Piper Sandler
Teva price target raised to $22 from $21 at Barclays
$22.00
(was $17.43)
Balaji Prasad
·
Barclays